Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)
Lithium
45.57
0.6%
Gold
2,672.20
0.7%
Copper
4.11
(1%)
Oil
70.13
1.58%
Bitcoin
98,431.01
4.32%
FTSE 100
8,149.27
0.79%
Nikkei 225
38,026.17
(0.85%)
Dow Jones
43,870.35
0.76%
Iron Ore
102.15
1.11%
USD/AUD
0.65
0%
Hang Seng
19,601.11
(0.23%)

Recce Pharmaceuticals Ltd

RCE

ASX

Recce Pharmaceuticals Ltd (RCE)is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives are RECCE 327, RECCE 435 and RECCE 529.

Latest Posts

Line Chart with Gradient
Price
$0.000
0 (0%)
At Close (AEST)
Related Companies
CYNATA THERAPEUTICS LIMITED
$CYP
ANTEOTECH LTD
$ADO
ZELIRA THERAPEUTICS LIMITED
$ZLD
ANAGENICS LIMITED
$AN1
TISSUE REPAIR LTD
$TRP

Leave a Comment on RCE


Comments for RCE

    Latest Posts

    Recce Pharmaceuticals Ltd (ASX: $RCE) Secures AUD $6.75M R&D Tax Rebate, Bolstering Innovation in Synthetic Anti-Infectives
    Health Care
    $rce
    Recce Pharmaceuticals Ltd (ASX: $RCE) Secures AUD $6.75M R&D Tax Rebate, Bolstering Innovation in Synthetic Anti-InfectivesRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), a pioneering developer of a new class of synthetic anti-infectives, has announced a...
    November 14, 2024
    recce-pharmaceuticals-asx-rce-advances-clinical-trials-for-anti-infective-drugs-rce
    Health Care $RCE
    Recce Pharmaceuticals (ASX: $RCE) advances clinical trials for anti-infective drugsInnovative treatments for sepsis and diabetic foot infections show promise in early-stage studies
    November 6, 2024
    recce-pharmaceuticals-asx-rce-advances-phase-ii-clinical-trial-for-skin-infections-rce
    Health Care $RCE
    Recce Pharmaceuticals (ASX: $RCE) advances phase II clinical trial for skin infections20 out of 30 patients achieve positive outcomes with RECCE® 327 Topical Gel, trial to conclude by 2024
    November 5, 2024
    recce-pharmaceuticals-asx-rce-reports-positive-interim-results-for-phase-ii-trial-rce
    Health Care $RCE
    Recce Pharmaceuticals (ASX: $RCE) reports positive interim results for phase II trialPromising safety and efficacy of RECCE® 327 Gel for bacterial skin infections in recent clinical trial
    October 28, 2024
    recce-pharmaceuticals-asx-rce-progresses-phase-ii-clinical-trial-for-skin-infections-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) progresses phase ii clinical trial for skin infections

    Phase II trial of RECCE® 327 topical gel shows promising antibacterial effect

    October 9, 2024
    recce-pharmaceuticals-asx-rce-progresses-clinical-trials-and-secures-additional-funding-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) progresses clinical trials and secures additional funding

    Positive data from clinical trials and new funding secured for anti-infective development

    July 26, 2024
    recce-pharmaceuticals-asx-rce-reports-positive-data-from-phase-i-ii-uti-urosepsis-rapid-infusion-clinical-trial-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) reports positive data from phase I/II UTI/urosepsis rapid infusion clinical trial

    Phase I/II trial demonstrates efficacy of RECCE® 327 at highest tested dose of 4,000mg

    June 28, 2024
    recce-pharmaceuticals-asx-rce-receives-ethics-approval-to-centralise-and-broaden-recce-327-gel-clinical-trials-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) receives ethics approval to centralise and broaden RECCE® 327 gel clinical trials

    Phase II clinical trial to assess R327 gel for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

    June 24, 2024
    recce-pharmaceuticals-asx-rce-receives-further-rd-tax-incentive-rebate-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) receives further R&D tax incentive rebate

    Australian government supports Recce Pharmaceuticals with AUD $2,624,860.47 cash refund for R&D activities

    June 18, 2024
    recce-pharmaceuticals-asx-rce-secures-who-recognition-for-recce-327-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) secures WHO recognition for RECCE® 327

    Added to WHO's list of Antibacterial Products in Clinical Development

    June 18, 2024
    recce-pharmaceuticals-asx-rce-doses-first-participants-in-uti-urosepsis-trial-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) doses first participants in uti/urosepsis trial

    Company successfully doses participants at 4,000mg intravenously in phase I/II trial

    May 15, 2024
    recce-pharmaceuticals-asx-rce-approves-high-dose-of-4000mg-for-urinary-tract-infection-urosepsis-trial-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) approves high dose of 4,000mg for urinary tract infection/urosepsis trial

    Independent Safety Committee clears R327 increase to 4,000mg intravenously over 30 minutes

    April 26, 2024
    recce-pharmaceuticals-asx-rce-progresses-clinical-trials-and-secures-usd-2-2m-grant-for-r327g-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) progresses clinical trials and secures USD $2.2M grant for R327G

    Phase I/II trials show promising results in UTI/Urosepsis and DFI, while R327G receives USD $2.2M grant for Burn Wound Infections

    April 8, 2024
    recce-pharmaceuticals-asx-rce-granted-patent-for-recce-anti-infectives-in-israel-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) granted patent for RECCE® anti-infectives in Israel

    State of Israel Patent Office grants new Patent Family 4 for RECCE's anti-infectives

    April 3, 2024
    recce-pharmaceuticals-asx-rce-completes-dosing-for-uti-urosepsis-clinical-trial-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) completes dosing for UTI/Urosepsis clinical trial

    Phase I/II trial of RECCE® 327 at fast infusion rates paves way for Phase II efficacy trial

    March 15, 2024
    recce-pharmaceuticals-asx-rce-secures-11-17m-rd-advance-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) secures $11.17m R&D advance

    Company receives non-dilutive cash for R&D rebate credits and future expenditure

    March 8, 2024
    recce-pharmaceuticals-asx-rce-demonstrates-efficacy-against-neisseria-gonorrhoeae-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) demonstrates efficacy against neisseria gonorrhoeae

    Positive results from Murdoch Children's Research Institute study show significant antibacterial activity

    January 12, 2024
    recce-pharmaceuticals-asx-rce-awarded-advanced-overseas-finding-for-synthetic-anti-viral-development-program-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) awarded advanced overseas finding for synthetic anti-viral development program

    Australian Government awards AU$11,172,377 for R&D applicable expenditure

    January 12, 2024
    recce-pharmaceuticals-asx-rce-awarded-overseas-rd-finding-for-synthetic-anti-infective-development-program-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX: $RCE) awarded overseas r&d finding for synthetic anti-infective development program

    Australian government awards AU$43,774,907 for R&D applicable expenditure

    January 12, 2024
    recce-pharmaceuticals-asxrce-awarded-advanced-overseas-finding-for-synthetic-anti-viral-development-program-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX:$RCE) awarded advanced overseas finding for synthetic anti-viral development program

    Australian Government awards AU$11,172,377 for R&D applicable expenditure

    December 19, 2023
    recce-pharmaceuticals-asxrce-awarded-overseas-rd-finding-for-synthetic-anti-infective-development-program-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX:$RCE) awarded overseas r&d finding for synthetic anti-infective development program

    Australian government awards AU$43,774,907 for R&D applicable expenditure

    December 14, 2023
    recce-pharmaceuticals-asxrce-demonstrates-efficacy-against-neisseria-gonorrhoeae-rce
    Health Care $RCE

    Recce Pharmaceuticals (ASX:$RCE) demonstrates efficacy against neisseria gonorrhoeae

    Positive results from Murdoch Children's Research Institute study show significant antibacterial activity

    December 14, 2023

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) approves high dose of 4,000mg for urinary tract infection/urosepsis trial

    Independent Safety Committee clears R327 increase to 4,000mg intravenously over 30 minutes

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) progresses clinical trials and secures USD $2.2M grant for R327G

    Phase I/II trials show promising results in UTI/Urosepsis and DFI, while R327G receives USD $2.2M grant for Burn Wound Infections

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) granted patent for RECCE® anti-infectives in Israel

    State of Israel Patent Office grants new Patent Family 4 for RECCE's anti-infectives

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) completes dosing for UTI/Urosepsis clinical trial

    Phase I/II trial of RECCE® 327 at fast infusion rates paves way for Phase II efficacy trial

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) secures $11.17m R&D advance

    Company receives non-dilutive cash for R&D rebate credits and future expenditure

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) demonstrates efficacy against neisseria gonorrhoeae

    Positive results from Murdoch Children's Research Institute study show significant antibacterial activity

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) awarded advanced overseas finding for synthetic anti-viral development program

    Australian Government awards AU$11,172,377 for R&D applicable expenditure

    RCE

    $RCE

    Recce Pharmaceuticals (ASX: $RCE) awarded overseas r&d finding for synthetic anti-infective development program

    Australian government awards AU$43,774,907 for R&D applicable expenditure

    RCE

    $RCE

    Recce Pharmaceuticals (ASX:$RCE) awarded advanced overseas finding for synthetic anti-viral development program

    Australian Government awards AU$11,172,377 for R&D applicable expenditure

    RCE

    $RCE

    Recce Pharmaceuticals (ASX:$RCE) awarded overseas r&d finding for synthetic anti-infective development program

    Australian government awards AU$43,774,907 for R&D applicable expenditure

    Load More
    No More Posts
    Related Companies
    CHIMERIC THERAPEUTICS LIMITED
    $CHM
    RADIOPHARM THERANOSTICS LIMITED
    $RAD
    CANN GROUP LIMITED
    $CAN
    AFT PHARMACEUTICALS LIMITED
    $AFP
    GENETIC SIGNATURES LIMITED
    $GSS

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions